
OPKO Health OPK
$ 1.14
-1.3%
Quarterly report 2025-Q2
added 07-31-2025
OPKO Health Total Current Liabilities 2011-2026 | OPK
Annual Total Current Liabilities OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 193 M | 200 M | 213 M | 330 M | 375 M | 249 M | 288 M | 312 M | 263 M | 252 M | 83.1 M | 91.8 M | 52.4 M | 18.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 375 M | 18.8 M | 209 M |
Total Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Biodesix
BDSX
|
14.3 M | $ 15.21 | 3.54 % | $ 1.97 B | ||
|
Bioventus
BVS
|
160 M | $ 9.12 | 1.33 % | $ 608 M | ||
|
Biomerica
BMRA
|
1.74 M | $ 2.12 | -0.47 % | $ 4.87 M | ||
|
Fulgent Genetics
FLGT
|
72.9 M | $ 16.37 | 0.24 % | $ 495 M | ||
|
Akumin
AKU
|
169 M | - | -17.87 % | $ 25.9 M | ||
|
Enzo Biochem
ENZ
|
24.8 M | - | -8.98 % | $ 14.8 K | ||
|
Check-Cap Ltd.
CHEK
|
1.81 M | - | - | $ 9.42 M | ||
|
Lantheus Holdings
LNTH
|
333 M | $ 75.01 | -0.96 % | $ 5.06 B | ||
|
Medpace Holdings
MEDP
|
1.34 B | $ 460.9 | 0.87 % | $ 13.3 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
13.8 M | - | - | $ 562 M | ||
|
Myriad Genetics
MYGN
|
134 M | $ 4.77 | 2.36 % | $ 442 M | ||
|
National Research Corporation
NRC
|
36.6 M | $ 17.42 | -0.51 % | $ 390 M | ||
|
DermTech
DMTK
|
13.4 M | - | -11.32 % | $ 2.94 M | ||
|
Aspira Women's Health
AWH
|
5.78 M | - | -6.19 % | $ 10.5 M | ||
|
Pacific Biosciences of California
PACB
|
72.8 M | $ 1.39 | -0.36 % | $ 417 M | ||
|
Co-Diagnostics
CODX
|
5.75 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Accelerate Diagnostics
AXDX
|
66.6 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
647 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | ||
|
Precipio
PRPO
|
3.14 M | $ 26.85 | -0.3 % | $ 34.8 M | ||
|
Personalis
PSNL
|
31.1 M | $ 7.7 | 1.18 % | $ 456 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.27 B | - | - | $ 10.7 B | ||
|
RadNet
RDNT
|
587 M | $ 60.0 | -2.83 % | $ 4.51 B | ||
|
Charles River Laboratories International
CRL
|
1.12 B | $ 159.79 | 1.13 % | $ 7.92 B | ||
|
IQVIA Holdings
IQV
|
8.34 B | $ 165.38 | -0.95 % | $ 28.4 B | ||
|
Senseonics Holdings
SENS
|
24.3 M | $ 6.74 | 1.81 % | $ 281 M | ||
|
Sotera Health Company
SHC
|
250 M | $ 13.89 | 0.07 % | $ 3.94 B | ||
|
Biocept
BIOC
|
5.51 M | - | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
108 M | - | - | $ 21.2 M | ||
|
BioNano Genomics
BNGO
|
22.9 M | $ 1.24 | -15.07 % | $ 6.75 M | ||
|
Neuronetics
STIM
|
30.5 M | $ 1.49 | -7.19 % | $ 98.3 M | ||
|
Mettler-Toledo International
MTD
|
1.2 B | $ 1 256.48 | 1.41 % | $ 25.9 B | ||
|
Interpace Biosciences
IDXG
|
10.6 M | $ 1.71 | 0.73 % | $ 7.5 M | ||
|
IDEXX Laboratories
IDXX
|
1.15 B | $ 574.14 | -0.76 % | $ 46.2 B | ||
|
Illumina
ILMN
|
1.55 B | $ 125.44 | 1.33 % | $ 19.9 B | ||
|
ICON Public Limited Company
ICLR
|
2.8 B | $ 101.04 | 0.68 % | $ 8.33 B | ||
|
Guardant Health
GH
|
303 M | $ 85.0 | 0.05 % | $ 10.7 B | ||
|
QIAGEN N.V.
QGEN
|
544 M | - | - | $ 10.6 B | ||
|
Twist Bioscience Corporation
TWST
|
91.4 M | $ 45.99 | 3.35 % | $ 2.75 B | ||
|
Celcuity
CELC
|
31.7 M | $ 103.41 | -3.13 % | $ 4.08 B | ||
|
Chembio Diagnostics
CEMI
|
39.3 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
2.82 B | $ 265.75 | 0.5 % | $ 22.1 B | ||
|
Motus GI Holdings
MOTS
|
3.27 M | - | -34.28 % | $ 263 K | ||
|
ENDRA Life Sciences
NDRA
|
605 K | $ 3.36 | -3.45 % | $ 1.8 M | ||
|
NeoGenomics
NEO
|
88.3 M | $ 8.05 | -0.62 % | $ 1.03 B | ||
|
Natera
NTRA
|
310 M | $ 195.23 | -2.43 % | $ 19.2 B | ||
|
CareDx, Inc
CDNA
|
89.8 M | $ 17.58 | 0.11 % | $ 937 M |